When Pfizer Inc. announced its plan to buy generic-drug maker Hospira for $17 billion in February, some observers yawned. Others sniped. “We believe the offer price … is significantly overvalued,”…
To view the full story, click the title link.
When Pfizer Inc. announced its plan to buy generic-drug maker Hospira for $17 billion in February, some observers yawned. Others sniped. “We believe the offer price … is significantly overvalued,”…
To view the full story, click the title link.